Head and Neck Cancer Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Debiopharm, Merck, GlaxoSmithKline, QBiotics Group Limited, Memgen, Inc., BioNTech, Alentis The

Head and Neck Cancer Pipeline constitutes 80+ key companies continuously working towards developing 100+ Head and Neck Cancer treatment therapies, analyzes DelveInsight.

Head and Neck Cancer Overview:

Head and neck cancer (HNC) refers to a group of malignancies originating in the head and neck region, most commonly in the squamous cells lining the mucosal surfaces of the mouth, throat, and larynx. These cancers are termed squamous cell carcinomas of the head and neck. Less commonly, HNC can also develop in the salivary glands, sinuses, or muscles and nerves in the area. Common sites include the larynx, nasal cavity, oral cavity, pharynx, paranasal sinuses, and salivary glands.

The development of HNC involves genetic and epigenetic changes, including mutations in tumor suppressor genes (e.g., TP53), activation of oncogenes (e.g., EGFR), and dysregulation of pathways like PI3K/AKT and MAPK. Contributing risk factors include tobacco and alcohol use, and for oropharyngeal cancers, human papillomavirus (HPV) infection. These factors disrupt normal cellular processes, leading to aggressive tumor growth and metastasis.

If HNC is suspected, a healthcare provider will review the patient's medical history, symptoms, and risk factors, and perform a physical exam. Diagnostic tests may include blood work, imaging studies like X-rays or CT scans, and biopsies to confirm cancer and check for HPV infection. Additional tests are conducted after diagnosis to determine the cancer's stage, which describes the extent of tumor spread and guides treatment decisions.

Treatment options include surgery, radiation therapy, chemotherapy, targeted therapy, immunotherapy, or combinations of these. The choice of treatment depends on the tumor's location, stage, and the patient's overall health. Patients with HPV-positive oropharyngeal cancers generally have better outcomes and higher cure rates than those with HPV-negative tumors. Consequently, clinical trials are exploring less intensive treatments, such as reduced radiation or immunotherapy, for HPV-positive cases.

Request for a detailed insights report on Head and Neck Cancer pipeline insights @ https://www.delveinsight.com/report-store/head-and-neck-cancer-hnc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Head and Neck Cancer Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Head and Neck Cancer Therapeutics Market.

Key Takeaways from the Head and Neck Cancer Pipeline Report

DelveInsight's Head and Neck Cancer pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Head and Neck Cancer treatment.
In September 2022, **NANOBIOTIX** announced the randomization of the first patient in Asia for NANORAY-312, a global Phase III trial evaluating NBTXR3 in elderly patients with locally advanced head and neck squamous cell carcinoma (HNSCC) who are ineligible for platinum-based chemotherapy.
In August 2022, **Genexine** began dosing the first patient in a Phase II clinical trial investigating a triple combination therapy for recurrent/metastatic HNSCC. This therapy combines two of Genexine's proprietary drugs, GX-188E (a therapeutic DNA vaccine) and GX-I7 (a long-acting interleukin-7), with Opdivo (nivolumab), a PD-1 immune checkpoint inhibitor.
In May 2022, **Calliditas Therapeutics** initiated a Phase II trial to evaluate the combination of setanaxib and pembrolizumab in patients with CAF-density tumors. The first subject was randomized in this proof-of-concept study targeting squamous cell carcinoma of the head and neck (SCCHN).
In May 2022, **Exelixis** shared results from a Phase II investigator-sponsored trial of cabozantinib (CABOMETYX®) with pembrolizumab in recurrent or metastatic HNSCC. The trial achieved an objective response rate of 54% (per RECIST version 1.1), with an overall clinical benefit rate of 91%. Median progression-free survival was 14.6 months, and the one-year overall survival rate was 68.4%.
In January 2022, the **FDA** accepted an investigational new drug application for RM-1995, a photoimmunotherapy treatment designed for patients with advanced cutaneous squamous cell carcinoma or head and neck squamous cell carcinoma.
Key Head and Neck Cancer companies such as Debiopharm, Merck, GlaxoSmithKline, QBiotics Group Limited, Memgen, Inc., BioNTech, Alentis Therapeutics AG, Beijing CorreGene Biotechnology, Coordination Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Sichuan Baili Pharmaceutical Co., Ltd., TILT Biotherapeutics Ltd., Coherus Biosciences, Inc., and others are evaluating new drugs for Head and Neck Cancer to improve the treatment landscape.
Promising Head and Neck Cancer pipeline therapies in various stages of development include Xevinapant, Dostarlimab, Tigilanol tiglate, MEM-288, and others.

Head and Neck Cancer Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Head and Neck Cancer Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Head and Neck Cancer treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Head and Neck Cancer market.

Download our free sample page report on Head and Neck Cancer pipeline insights @ https://www.delveinsight.com/sample-request/head-and-neck-cancer-hnc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Head and Neck Cancer Emerging Drugs

Xevinapant: Debiopharm/Merck
Dostarlimab: GlaxoSmithKline
Tigilanol tiglate: QBiotics Group Limited
MEM-288: Memgen, Inc.

Head and Neck Cancer Companies

Over 80 key companies are actively working on therapies for head and neck cancer. Among them, GlaxoSmithKline and Debiopharm/Merck have drug candidates that have reached the most advanced stage of development, specifically Phase III.

DelveInsight's report covers around 100+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Head and Neck Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Head and Neck Cancer Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Head and Neck Cancer Therapies and Key Companies: Head and Neck Cancer Clinical Trials and advancements @ https://www.delveinsight.com/report-store/head-and-neck-cancer-hnc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Head and Neck Cancer Pipeline Therapeutic Assessment
• Head and Neck Cancer Assessment by Product Type
• Head and Neck Cancer By Stage
• Head and Neck Cancer Assessment by Route of Administration
• Head and Neck Cancer Assessment by Molecule Type

Download Head and Neck Cancer Sample report to know in detail about the Head and Neck Cancer treatment market @ Head and Neck Cancer Therapeutic Assessment @ https://www.delveinsight.com/sample-request/head-and-neck-cancer-hnc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Head and Neck Cancer Current Treatment Patterns
4. Head and Neck Cancer - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Head and Neck Cancer Late-Stage Products (Phase-III)
7. Head and Neck Cancer Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Head and Neck Cancer Discontinued Products
13. Head and Neck Cancer Product Profiles
14. Head and Neck Cancer Key Companies
15. Head and Neck Cancer Key Products
16. Dormant and Discontinued Products
17. Head and Neck Cancer Unmet Needs
18. Head and Neck Cancer Future Perspectives
19. Head and Neck Cancer Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Head and Neck Cancer Pipeline Reports Offerings: https://www.delveinsight.com/report-store/head-and-neck-cancer-hnc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.